Abstract
The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.
| Original language | English |
|---|---|
| Pages (from-to) | 163-167 |
| Number of pages | 5 |
| Journal | International Journal of Oncology |
| Volume | 11 |
| Issue number | 1 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Aromatase inhibitor
- Breast cancer
- Hormonal treatment
- Insulin-like growth factors
- Postmenopause
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. / Ferrari, Leonardo; Bajetta, Emilio; Seregni, Ettore; Martinetti, Antonia; Zilembo, Nicoletta; Noberasco, Cristina; Buzzoni, Roberto; Botti, Carlo; Massaron, Simonetta; Bichisao, Ettore; Celio, Luigi; Bombardieri, Emilio.
In: International Journal of Oncology, Vol. 11, No. 1, 1997, p. 163-167.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer
AU - Ferrari, Leonardo
AU - Bajetta, Emilio
AU - Seregni, Ettore
AU - Martinetti, Antonia
AU - Zilembo, Nicoletta
AU - Noberasco, Cristina
AU - Buzzoni, Roberto
AU - Botti, Carlo
AU - Massaron, Simonetta
AU - Bichisao, Ettore
AU - Celio, Luigi
AU - Bombardieri, Emilio
PY - 1997
Y1 - 1997
N2 - The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.
AB - The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.
KW - Aromatase inhibitor
KW - Breast cancer
KW - Hormonal treatment
KW - Insulin-like growth factors
KW - Postmenopause
UR - http://www.scopus.com/inward/record.url?scp=8544237726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8544237726&partnerID=8YFLogxK
M3 - Article
C2 - 21528196
AN - SCOPUS:8544237726
VL - 11
SP - 163
EP - 167
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 1
ER -